Xu and colleagues examined the role of AGR3 in invasive ductal carcinoma (IDC) and found that AGR3 was predominantly expressed in luminal subtypes, with AGR3 expression associated with various outcomes, including a higher risk of recurrence and metastasis, increased cancer cell invasion and proliferation, and enhanced sensitivity to chemotherapeutic 5-fluoropyrimidines [150]. Here, AGR3 is linked to invasive ductal breast carcinoma.